Do analysts prefer GMTX or CLYM?

Climb Bio has a consensus target price of $26.92, indicating a potential upside of 91.62%. Given Climb Bio's stronger consensus rating and higher probable upside, analysts clearly believe Climb Bio is more favorable than Gemini Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gemini Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Climb Bio 1 Sell rating(s) 0 Hold rating(s) 13 Buy rating(s) 2 Strong Buy rating(s) 3.00

Which has higher valuation & earnings, GMTX or CLYM?

Gemini Therapeutics is trading at a lower price-to-earnings ratio than Climb Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Gemini Therapeutics N/A N/A -$71.87M -$1.00 N/A Climb Bio N/A N/A -$59.85M -$0.83 N/A

Is GMTX or CLYM more profitable?

Climb Bio's return on equity of -31.79% beat Gemini Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Gemini Therapeutics N/A -38.78% -35.88% Climb Bio N/A -31.79% -30.79%

Which has better valuation and earnings, QURE or CLYM?

Climb Bio has lower revenue, but higher earnings than uniQure. Climb Bio is trading at a lower price-to-earnings ratio than uniQure, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio uniQure $18.67M 163.46 -$198.97M -$4.01 N/A Climb Bio N/A N/A -$59.85M -$0.83 N/A

Is QURE or CLYM more profitable?

Climb Bio has a net margin of 0.00% compared to uniQure's net margin of -1,350.73%. Climb Bio's return on equity of -31.79% beat uniQure's return on equity. Company Net Margins Return on Equity Return on Assets uniQure -1,350.73% -111.96% -29.01% Climb Bio N/A -31.79% -30.79%

Does the media prefer QURE or CLYM?

In the previous week, Climb Bio had 6 more articles in the media than uniQure. MarketBeat recorded 7 mentions for Climb Bio and 1 mentions for uniQure. uniQure's average media sentiment score of 1.56 beat Climb Bio's score of 0.77 indicating that uniQure is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment uniQure 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Climb Bio 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is CLDX or CLYM more profitable?

Climb Bio's return on equity of -31.79% beat Celldex Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Celldex Therapeutics N/A -52.35% -47.61% Climb Bio N/A -31.79% -30.79%

Does the media refer more to CLDX or CLYM?

In the previous week, Climb Bio had 2 more articles in the media than Celldex Therapeutics. MarketBeat recorded 7 mentions for Climb Bio and 5 mentions for Celldex Therapeutics. Climb Bio's average media sentiment score of 0.77 beat Celldex Therapeutics' score of 0.76 indicating that Climb Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Celldex Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Climb Bio 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is IMNM or CLYM more profitable?

Climb Bio's return on equity of -31.79% beat Immunome's return on equity. Company Net Margins Return on Equity Return on Assets Immunome N/A -50.56% -46.93% Climb Bio N/A -31.79% -30.79%

Does the media prefer IMNM or CLYM?

In the previous week, Climb Bio had 3 more articles in the media than Immunome. MarketBeat recorded 7 mentions for Climb Bio and 4 mentions for Immunome. Climb Bio's average media sentiment score of 0.77 beat Immunome's score of 0.51 indicating that Climb Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunome 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Climb Bio 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings and valuation, ZLAB or CLYM?

Climb Bio has lower revenue, but higher earnings than Zai Lab. Climb Bio is trading at a lower price-to-earnings ratio than Zai Lab, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Zai Lab $460.16M 6.35 -$175.54M -$1.71 N/A Climb Bio N/A N/A -$59.85M -$0.83 N/A

Is ZLAB or CLYM more profitable?

Climb Bio has a net margin of 0.00% compared to Zai Lab's net margin of -41.86%. Zai Lab's return on equity of -27.43% beat Climb Bio's return on equity. Company Net Margins Return on Equity Return on Assets Zai Lab -41.86% -27.43% -16.72% Climb Bio N/A -31.79% -30.79%

Climb Bio (CLYM) Competitors

$14.05 -0.01 (-0.07%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$14.34 +0.29 (+2.04%)

As of 09/18/2026 07:56 PM Eastern

Compare

CLYM vs. GMTX, QURE, CLDX, IMNM, and ZLAB

Should you buy Climb Bio stock or one of its competitors? Climb Bio's main competitors and comparable companies include Gemini Therapeutics (GMTX), uniQure (QURE), Celldex Therapeutics (CLDX), Immunome (IMNM), and Zai Lab (ZLAB). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Climb Bio compare to Gemini Therapeutics?

Gemini Therapeutics (NASDAQ:GMTX) and Climb Bio (NASDAQ:CLYM) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, analyst recommendations, risk, dividends, media sentiment and valuation.

Climb Bio's return on equity of -31.79% beat Gemini Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gemini Therapeutics	N/A	-38.78%	-35.88%
Climb Bio	N/A	-31.79%	-30.79%

Gemini Therapeutics is trading at a lower price-to-earnings ratio than Climb Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gemini Therapeutics	N/A	N/A	-$71.87M	-$1.00	N/A
Climb Bio	N/A	N/A	-$59.85M	-$0.83	N/A

In the previous week, Climb Bio had 7 more articles in the media than Gemini Therapeutics. MarketBeat recorded 7 mentions for Climb Bio and 0 mentions for Gemini Therapeutics. Climb Bio's average media sentiment score of 0.77 beat Gemini Therapeutics' score of 0.00 indicating that Climb Bio is being referred to more favorably in the news media.

Company	Overall Sentiment
Gemini Therapeutics	Neutral
Climb Bio	Positive

Climb Bio has a consensus target price of $26.92, indicating a potential upside of 91.62%. Given Climb Bio's stronger consensus rating and higher probable upside, analysts clearly believe Climb Bio is more favorable than Gemini Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gemini Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Climb Bio	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	2 Strong Buy rating(s)	3.00

75.4% of Gemini Therapeutics shares are held by institutional investors. Comparatively, 69.8% of Climb Bio shares are held by institutional investors. 12.9% of Gemini Therapeutics shares are held by company insiders. Comparatively, 2.6% of Climb Bio shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Gemini Therapeutics has a beta of -0.12, indicating that its share price is 112% less volatile than the broader market. Comparatively, Climb Bio has a beta of 0.09, indicating that its share price is 91% less volatile than the broader market.

Summary

Climb Bio beats Gemini Therapeutics on 12 of the 14 factors compared between the two stocks.

How does Climb Bio compare to uniQure?

uniQure (NASDAQ:QURE) and Climb Bio (NASDAQ:CLYM) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, institutional ownership, analyst recommendations, risk, valuation, media sentiment, dividends and profitability.

Climb Bio has a net margin of 0.00% compared to uniQure's net margin of -1,350.73%. Climb Bio's return on equity of -31.79% beat uniQure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
uniQure	-1,350.73%	-111.96%	-29.01%
Climb Bio	N/A	-31.79%	-30.79%

78.8% of uniQure shares are held by institutional investors. Comparatively, 69.8% of Climb Bio shares are held by institutional investors. 4.7% of uniQure shares are held by company insiders. Comparatively, 2.6% of Climb Bio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Climb Bio had 6 more articles in the media than uniQure. MarketBeat recorded 7 mentions for Climb Bio and 1 mentions for uniQure. uniQure's average media sentiment score of 1.56 beat Climb Bio's score of 0.77 indicating that uniQure is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
uniQure	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Climb Bio	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

uniQure has a beta of 0.94, suggesting that its stock price is 6% less volatile than the broader market. Comparatively, Climb Bio has a beta of 0.09, suggesting that its stock price is 91% less volatile than the broader market.

Climb Bio has lower revenue, but higher earnings than uniQure. Climb Bio is trading at a lower price-to-earnings ratio than uniQure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
uniQure	$18.67M	163.46	-$198.97M	-$4.01	N/A
Climb Bio	N/A	N/A	-$59.85M	-$0.83	N/A

uniQure currently has a consensus target price of $65.00, indicating a potential upside of 47.73%. Climb Bio has a consensus target price of $26.92, indicating a potential upside of 91.62%. Given Climb Bio's stronger consensus rating and higher possible upside, analysts plainly believe Climb Bio is more favorable than uniQure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
uniQure	1 Sell rating(s)	2 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.76
Climb Bio	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	2 Strong Buy rating(s)	3.00

Summary

uniQure and Climb Bio tied by winning 8 of the 16 factors compared between the two stocks.

How does Climb Bio compare to Celldex Therapeutics?

Celldex Therapeutics (NASDAQ:CLDX) and Climb Bio (NASDAQ:CLYM) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, dividends, media sentiment, risk, analyst recommendations, valuation and institutional ownership.

Celldex Therapeutics has a beta of 0.84, indicating that its share price is 16% less volatile than the broader market. Comparatively, Climb Bio has a beta of 0.09, indicating that its share price is 91% less volatile than the broader market.

69.8% of Climb Bio shares are held by institutional investors. 5.2% of Celldex Therapeutics shares are held by company insiders. Comparatively, 2.6% of Climb Bio shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Climb Bio's return on equity of -31.79% beat Celldex Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Celldex Therapeutics	N/A	-52.35%	-47.61%
Climb Bio	N/A	-31.79%	-30.79%

In the previous week, Climb Bio had 2 more articles in the media than Celldex Therapeutics. MarketBeat recorded 7 mentions for Climb Bio and 5 mentions for Celldex Therapeutics. Climb Bio's average media sentiment score of 0.77 beat Celldex Therapeutics' score of 0.76 indicating that Climb Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Celldex Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Climb Bio	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Celldex Therapeutics currently has a consensus target price of $56.42, suggesting a potential upside of 47.53%. Climb Bio has a consensus target price of $26.92, suggesting a potential upside of 91.62%. Given Climb Bio's stronger consensus rating and higher probable upside, analysts clearly believe Climb Bio is more favorable than Celldex Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Celldex Therapeutics	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.85
Climb Bio	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	2 Strong Buy rating(s)	3.00

Climb Bio has lower revenue, but higher earnings than Celldex Therapeutics. Climb Bio is trading at a lower price-to-earnings ratio than Celldex Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Celldex Therapeutics	$1.54M	1,949.99	-$258.76M	-$4.35	N/A
Climb Bio	N/A	N/A	-$59.85M	-$0.83	N/A

Summary

Climb Bio beats Celldex Therapeutics on 11 of the 15 factors compared between the two stocks.

How does Climb Bio compare to Immunome?

Immunome (NASDAQ:IMNM) and Climb Bio (NASDAQ:CLYM) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, dividends, risk, institutional ownership, profitability and valuation.

In the previous week, Climb Bio had 3 more articles in the media than Immunome. MarketBeat recorded 7 mentions for Climb Bio and 4 mentions for Immunome. Climb Bio's average media sentiment score of 0.77 beat Immunome's score of 0.51 indicating that Climb Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunome	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Climb Bio	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Immunome presently has a consensus price target of $34.64, indicating a potential upside of 44.50%. Climb Bio has a consensus price target of $26.92, indicating a potential upside of 91.62%. Given Climb Bio's stronger consensus rating and higher probable upside, analysts plainly believe Climb Bio is more favorable than Immunome.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunome	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.85
Climb Bio	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	2 Strong Buy rating(s)	3.00

Climb Bio has lower revenue, but higher earnings than Immunome. Climb Bio is trading at a lower price-to-earnings ratio than Immunome, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunome	$6.94M	392.29	-$212.39M	-$2.53	N/A
Climb Bio	N/A	N/A	-$59.85M	-$0.83	N/A

Immunome has a beta of 2.13, indicating that its stock price is 113% more volatile than the broader market. Comparatively, Climb Bio has a beta of 0.09, indicating that its stock price is 91% less volatile than the broader market.

44.6% of Immunome shares are owned by institutional investors. Comparatively, 69.8% of Climb Bio shares are owned by institutional investors. 7.2% of Immunome shares are owned by insiders. Comparatively, 2.6% of Climb Bio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Climb Bio's return on equity of -31.79% beat Immunome's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunome	N/A	-50.56%	-46.93%
Climb Bio	N/A	-31.79%	-30.79%

Summary

Climb Bio beats Immunome on 11 of the 15 factors compared between the two stocks.

How does Climb Bio compare to Zai Lab?

Zai Lab (NASDAQ:ZLAB) and Climb Bio (NASDAQ:CLYM) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, valuation, risk, institutional ownership, dividends, analyst recommendations and media sentiment.

In the previous week, Climb Bio had 7 more articles in the media than Zai Lab. MarketBeat recorded 7 mentions for Climb Bio and 0 mentions for Zai Lab. Climb Bio's average media sentiment score of 0.77 beat Zai Lab's score of -0.45 indicating that Climb Bio is being referred to more favorably in the news media.

Company	Overall Sentiment
Zai Lab	Neutral
Climb Bio	Positive

Zai Lab has a beta of 0.83, meaning that its stock price is 17% less volatile than the broader market. Comparatively, Climb Bio has a beta of 0.09, meaning that its stock price is 91% less volatile than the broader market.

Climb Bio has lower revenue, but higher earnings than Zai Lab. Climb Bio is trading at a lower price-to-earnings ratio than Zai Lab, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zai Lab	$460.16M	6.35	-$175.54M	-$1.71	N/A
Climb Bio	N/A	N/A	-$59.85M	-$0.83	N/A

41.7% of Zai Lab shares are held by institutional investors. Comparatively, 69.8% of Climb Bio shares are held by institutional investors. 4.9% of Zai Lab shares are held by insiders. Comparatively, 2.6% of Climb Bio shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Zai Lab presently has a consensus target price of $37.25, suggesting a potential upside of 44.94%. Climb Bio has a consensus target price of $26.92, suggesting a potential upside of 91.62%. Given Climb Bio's stronger consensus rating and higher possible upside, analysts clearly believe Climb Bio is more favorable than Zai Lab.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zai Lab	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
Climb Bio	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	2 Strong Buy rating(s)	3.00

Climb Bio has a net margin of 0.00% compared to Zai Lab's net margin of -41.86%. Zai Lab's return on equity of -27.43% beat Climb Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zai Lab	-41.86%	-27.43%	-16.72%
Climb Bio	N/A	-31.79%	-30.79%

Summary

Climb Bio beats Zai Lab on 10 of the 16 factors compared between the two stocks.

Get Climb Bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CLYM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CLYM vs. The Competition

Export

Metric	Climb Bio	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$807.55M	$3.91B	$7.25B	$13.13B
Dividend Yield	N/A	3.65%	2.57%	12.94%
P/E Ratio	-16.93	14.08	273.81	25.39
Price / Sales	N/A	1,407.75	692.78	109.00
Price / Cash	N/A	110.75	77.42	51.66
Price / Book	4.18	15.45	10.45	6.33
Net Income	-$59.85M	-$22.78M	$3.48B	$358.24M
7 Day Performance	-1.40%	-1.22%	0.88%	1.17%
1 Month Performance	-18.97%	-4.44%	-1.59%	-2.59%
1 Year Performance	508.23%	37.78%	18.08%	5.97%

Climb Bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CLYM Climb Bio	3.5256 of 5 stars	$14.05 -0.1%	$26.92 +91.6%	+527.2%	$807.55M	N/A	N/A	29	Analyst Upgrade Insider Trade High Trading Volume
GMTX Gemini Therapeutics	N/A	$74.14 -3.1%	N/A	+13.3%	$3.21B	N/A	N/A	30	High Trading Volume
QURE uniQure	3.6969 of 5 stars	$44.51 +0.1%	$65.00 +46.0%	+198.5%	$3.09B	$16.10M	N/A	221	Positive News
CLDX Celldex Therapeutics	2.138 of 5 stars	$36.90 -3.1%	$56.42 +52.9%	+47.5%	$2.90B	$1.54M	N/A	150	News Coverage
IMNM Immunome	3.0609 of 5 stars	$24.67 -1.2%	$34.64 +40.4%	+143.4%	$2.80B	$6.94M	N/A	40	Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CLYM) was last updated on 9/19/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Climb Bio (CLYM) Competitors

CLYM vs. GMTX, QURE, CLDX, IMNM, and ZLAB

How does Climb Bio compare to Gemini Therapeutics?

Summary

How does Climb Bio compare to uniQure?

Summary

How does Climb Bio compare to Celldex Therapeutics?

Summary

How does Climb Bio compare to Immunome?

Summary

How does Climb Bio compare to Zai Lab?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLYM vs. The Competition

Climb Bio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Climb Bio (CLYM) Competitors

CLYM vs. GMTX, QURE, CLDX, IMNM, and ZLAB

How does Climb Bio compare to Gemini Therapeutics?

Is GMTX or CLYM more profitable?

Which has higher valuation & earnings, GMTX or CLYM?

Does the media prefer GMTX or CLYM?

Do analysts prefer GMTX or CLYM?

Do institutionals & insiders believe in GMTX or CLYM?

Which has more volatility & risk, GMTX or CLYM?

Summary

How does Climb Bio compare to uniQure?

Is QURE or CLYM more profitable?

Do insiders and institutionals believe in QURE or CLYM?

Does the media prefer QURE or CLYM?

Which has more volatility and risk, QURE or CLYM?

Which has better valuation and earnings, QURE or CLYM?

Do analysts prefer QURE or CLYM?

Summary

How does Climb Bio compare to Celldex Therapeutics?

Which has more volatility & risk, CLDX or CLYM?

Do insiders & institutionals have more ownership in CLDX or CLYM?

Is CLDX or CLYM more profitable?

Does the media refer more to CLDX or CLYM?

Do analysts rate CLDX or CLYM?

Which has preferable earnings & valuation, CLDX or CLYM?

Summary

How does Climb Bio compare to Immunome?

Does the media prefer IMNM or CLYM?

Do analysts rate IMNM or CLYM?

Which has higher valuation & earnings, IMNM or CLYM?

Which has more risk & volatility, IMNM or CLYM?

Do insiders & institutionals believe in IMNM or CLYM?

Is IMNM or CLYM more profitable?

Summary

How does Climb Bio compare to Zai Lab?

Does the media refer more to ZLAB or CLYM?

Which has more risk and volatility, ZLAB or CLYM?

Which has better earnings and valuation, ZLAB or CLYM?

Do insiders and institutionals hold more shares of ZLAB or CLYM?

Do analysts rate ZLAB or CLYM?

Is ZLAB or CLYM more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLYM vs. The Competition

Climb Bio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools